Structure, function, and inhibition along the reaction coordinate of CTX-M β-lactamases

被引:104
作者
Chen, Y
Shoichet, B
Bonnet, R
机构
[1] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA
[2] CHU, Fac Med, Bacteriol Lab, F-63001 Clermont Ferrand, France
关键词
D O I
10.1021/ja042850a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
CTX-M enzymes are an emerging group of extended spectrum beta-lactamases (ESBLs) that hydrolyze not only the penicillins but also the first-, second-, and third-generation cephalosporins. Although they have become the most frequently observed ESBLs in certain areas, there are few effective inhibitors and relatively little is known about their detailed mechanism. Here we describe the X-ray crystal structures of CTX-M enzymes in complex with different transition-state analogues and beta-lactam inhibitors, representing the enzyme as it progresses from its acylation transition state to its acyl enzyme complex to the deacylation transition state. As the enzyme moves along this reaction coordinate, two key catalytic residues, Lys73 and Glu166, change conformations, tracking the state of the reaction. Unexpectedly, the acyl enzyme complex with the beta-lactam inhibitor cefoxitin still has the catalytic water bound; this water had been predicted to be displaced by the unusual 7 alpha-methoxy of the inhibitor. Instead, the 7 alpha-group appears to inhibit by preventing the formation of the deacylation transition state through steric hindrance. From an inhibitor design standpoint, we note that the best of the reversible inhibitors, a ceftazidime-like boronic acid compound, binds to CTX-M-16 with a K-i value of 4 nM. When used together in cell culture, this inhibitor reversed cefotaxime resistance in CTX-M-producing bacteria. The structure of its complex with CTX-M enzyme and the structural view of the reaction coordinate described here provide templates for inhibitor design and intervention to combat this family of antibiotic resistance enzymes.
引用
收藏
页码:5423 / 5434
页数:12
相关论文
共 47 条
[1]  
BAZOULI M, 1998, FEMS MICROBIOL LETT, V169, P289
[2]   Functional analyses of AmpC β-lactamase through differential stability [J].
Beadle, BM ;
McGovern, SL ;
Patera, A ;
Shoichet, BK .
PROTEIN SCIENCE, 1999, 8 (09) :1816-1824
[3]  
BECKTEL WJ, 1987, BIOPOLYMERS, V26, P18759
[4]   A novel class A extended-spectrum β-lactamase (BES-1) in Serratia marcescens isolated in Brazil [J].
Bonnet, R ;
Sampaio, JLM ;
Chanal, C ;
Sirot, D ;
De Champs, C ;
Viallard, JL ;
Labia, R ;
Sirot, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3061-3068
[5]   Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240→Gly [J].
Bonnet, R ;
Dutour, C ;
Sampaio, JLM ;
Chanal, C ;
Sirot, D ;
Labia, R ;
De Champs, C ;
Sirot, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2269-2275
[6]   Growing group of extended-spectrum β-lactamases:: The CTX-M enzymes [J].
Bonnet, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :1-14
[7]   Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat [J].
Bradford, PA .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :933-951
[8]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[9]   Energetic, structural, and antimicrobial analyses of β-lactam side chain recognition by β-lactamases [J].
Caselli, E ;
Powers, RA ;
Blasczcak, LC ;
Wu, CYE ;
Prati, F ;
Shoichet, BK .
CHEMISTRY & BIOLOGY, 2001, 8 (01) :17-31
[10]   Problems encountered in the characterization of IRT beta-lactamase-producing clinical Escherichia coli isolates intermediate-resistant to cephalothin [J].
Chaibi, EB ;
Farzaneh, S ;
Morand, A ;
Peduzzi, J ;
Barthelemy, M ;
Sirot, D ;
Labia, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (01) :190-191